期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
High-Efficiency Broadband Near-Infrared Single-Photon Frequency Upconversion and Detection
1
作者 jian-hui ma Hui-Qin Hu +3 位作者 Yu Chen Guang-Jian Xu Hai-Feng Pan E Wu 《Chinese Physics Letters》 SCIE CAS CSCD 2020年第3期17-21,共5页
We propose and demonstrate a high efficiency broadband near infrared single-photon upconversion and detection with a broadband pump laser based on sum frequency conversion in the PPLN crystal.By using a pump laser cen... We propose and demonstrate a high efficiency broadband near infrared single-photon upconversion and detection with a broadband pump laser based on sum frequency conversion in the PPLN crystal.By using a pump laser centered at 1040 nm with a spectral bandwidth of 10 nm,the signal single-photons centered at 1562 nm with a broadband bandwidth up to 7.2 nm are frequency-converted from the near infrared to the visible regime.A maximum conversion efficiency of 18.8%is achieved,while the background noise is measured to be only1.2×10^-3 counts/pulse.The corresponding spectral linewidth of the upconverted photons is 0.2 nm.This scheme of broadband infrared single-photon upconversion and detection provides potential solutions in infrared laser ranging,broadband infrared imaging and quantum key distribution. 展开更多
关键词 PUMP EFFICIENCY INFRARED
下载PDF
Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy
2
作者 Yan Song Chun-Xia Du +10 位作者 Wen Zhang Yong-Kun Sun Lin Yang Cheng-Xu Cui Yihe-Bali Chi Jian-Zhong Shou Ai-Ping Zhou Chang-Ling Li jian-hui ma Jin-Nan Wang Yan Sun 《Chinese Medical Journal》 SCIE CAS CSCD 2016年第5期530-535,共6页
Background:The metastatic renal cell carcinoma (mRCC) patients treated with upfront cytoreductive nephrectomy combined with α-interferon yields additional overall survival (OS) benefits.It is unclear whether mRC... Background:The metastatic renal cell carcinoma (mRCC) patients treated with upfront cytoreductive nephrectomy combined with α-interferon yields additional overall survival (OS) benefits.It is unclear whether mRCC patients treated with vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) will benefit from such cytoreductive nephrectomy either.The aim of the study was to identify variables for selection of patients who would benefit from upfront cytoreductive nephrectomy for mRCC treated with VEGFR-TKI.Methods:Clinical data on 74 patients enrolled in 5 clinical trials conducted in Cancer Hospital (Institute),Chinese Academy of Medical Sciences from January 2006 to January 2014 were reviewed retrospectively.The survival analysis was performed by the Kaplan-Meier method.Comparisons between patient groups were performed by Chi-square test.A Cox regression model was adopted for analysis of multiple factors affecting survival,with a significance level of α =0.05.Results:Fifty-one patients underwent cytoreductive nephrectomy followed by targeted therapy (cytoreductive nephrectomy group) and 23 patients were treated with targeted therapy alone (noncytoreductive nephrectomy group).The median OS was 32.2 months and 23.0 months in cytoreductive nephrectomy and noncytoreductive nephrectomy groups,respectively (P =0.041).Age ≤45 years (P =0.002),a low or high body mass index (BMI 〈19 or 〉30 kg/m2) (P =0.008),a serum lactate dehydrogenase (LDH) concentration 〉 1.5 × upper limit of normal (P =0.025),a serum calcium concentration 〉1 0 mg/ml (P =0.034),and 3 or more metastatic sites (P =0.023) were independent preoperative risk factors for survival.The patients only with 0-2 risk factors benefited from upfront cytoreductive nephrectomy in terms of OS when compared with the patients treated with targeted therapy alone (40.0 months vs.23.2 months,P =0.042),while those with more than 2 risk factors did not.Conclusions:Five risk factors (age,BMI,LDH,serum calcium,and number of metastatic sites) seemed to be helpful for selecting patients who would benefit from undergoing upfront cytoreductive nephrectomy. 展开更多
关键词 Cytoreductive Nephrectomy Metastatic Renal Cell Carcinoma Targeted Therapy
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部